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As the roll-out of antiretrovirals (ARVs) to people living with 
HIV/AIDS (PLWHA) continues to increase in South Africa, so too 
does the need to integrate mental health services into HIV care. 
In this editorial, we argue that the role of mental health in ARV 
programmes is central. The prevalence of mental disorders in 
PLWHA is higher than in the general population, and the impact 
of these conditions is substantial. Screening tools for mental 
disorders are both available and feasible. These should be 
incorporated into routine ARV care, with support from dedicated 
HIV mental health services. 
In PLWHA there is growing evidence of an increased prevalence 
of mental disorders compared with the general population. For 
example, in a meta-analysis of 10 studies, major depression 
was nearly twice as common in PLWHA.1 Similarly, in the HIV 
Cost and Services Utilization Study (HCSUS) conducted in the 
USA,2 the prevalence of depressive, anxiety and substance 
use disorders in PLWHA was at least twice that reported in the 
NCS-R. In the HCSUS, the prevalence of alcohol and substance 
abuse combined was reported as 50.1%, while neurocognitive 
disorders affect as many as 30% of PLWHA, particularly in 
late stages.3 Mental disorders found to be highly prevalent in a 
South African ARV clinic include major depression (34.9%), post-
traumatic stress disorder (14.8%) and alcohol abuse (10.1%).4 
In addition to these mental disorders, neurocognitive disorders 
(NCDs) are emerging as a new challenge in the era of ARVs. 
They often persist despite the use of ARVs, with consequent 
neurodegeneration.5 NCDs, with the typical sub-cortical pattern, 
are being encountered increasingly in ARV clinic populations. 
Frank HIV dementia (HIV-D) may be occurring less frequently than 
before, but as the duration of illness increases with ARVs, it is now 
recognised that prevalences may actually be increasing.6 Minor 
forms of NCD also occur, and with greater frequency than HIV-D. 
While these forms of neurological disease are less disabling, they 
nonetheless also result in a significant burden of disease.5 
While it is known that NCDs are highly prevalent, and that 
minor forms are often not detected, a unique opportunity exists 
to address some of these questions. While all patients entering 
ARV care should be screened for NCD, the issue is whether or 
not individuals with CD4 counts greater than 200 cells/µl and 
demonstrable neurocognitive impairment should be commenced 
on ARVs for their relative neuroprotective effects. How busy 
primary care clinics integrate this screening into routine care 
should be discussed and researched. 
The impact of mental disorders on outcomes in PLWHA is now 
undisputed. They affect adherence, mortality and quality of 
life.7 In addition, many mental disorders increase the probability 
of engaging in risk behaviours,8 and are aggravated by or 
caused by ARV treatment.9 In the context of the large numbers 
of PLWHA in South Africa who are infected and who access 
ARV care, this burden is substantial. South Africa has the largest 
number of people infected with HIV worldwide.10 With South 
Africa deploying one of the more successful ARV roll-outs in the 
developing world, more than half of PLWHA in the Western 
Cape will receive ARVs.11 These growing numbers of patients 
accessing HIV care have seen the rates of retention in care falling. 
Of the cohort commencing ARVs in 2005, 13.8% were no longer 
in care at 2 years.11 Of this number, approximately 40% are 
people lost to follow-up (LTFU). LTFU is a crude proxy measure 
for poor adherence. Substance abuse and mental disorders are 
common reasons for poor adherence.12 
With all of these conditions affecting large numbers of PLWHA, 
screening programmes for mental illness are increasingly 
being regarded as essential to HIV care. In South Africa, it is a 
requirement that patients enrolled onto ARVs receive some form 
of screening for both depression and alcohol abuse. It is our 
impression that this is done with varying accuracy and efficacy. 
While Patel et al. have argued that the training of primary care 
physicians leads to transient improvements in detection, screening 
tools may actually improve outcomes in general primary care 
clinics.13 Brief instruments for these settings do exist (such as the 
General Health Questionnaire and the Kessler-10 item scale),14,15 
but few are aimed at the specific problems encountered in ARV 
clinic populations. A MEDLINE search for such a tool yielded 
only the Substance Abuse and Mental Illness Symptoms Screener 
(SAMISS), a tool validated in PLWHA in the USA.16 It includes 
screening questions for alchohol and substance abuse, major 
depression, panic disorder and PTSD, as well as adjustment 
disorder. These are an important group of disorders commonly 
encountered in the pre-ARV treatment group. Other disorder-
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specific tools have been validated in South Africa, namely the 
Alcohol Use Disorders Identification Test (AUDIT), the Centres for 
Epidemiological Study-Depression Scale (CES-D) and the Harvard 
Trauma Scale (HTS).17 The combination of these tools would 
however prove too lengthy.
Together with the SAMISS, a screen for neurocognitive disorder 
should be done on all patients commencing ARVs, those failing 
first-line treatments, and those who have been on ARVs for more 
than 2 years. The International HIV Dementia Scale18 is a suitable 
brief screening tool for this setting. Together the SAMISS and 
IHDS screen takes 10 - 12 minutes. The sensitivity and specificity 
of the SAMISS are 97% and 44% respectively,16 while those of 
the IHDS were reported to be 80% and 55% respectively.18 The 
high sensitivities would normally result in a high degree of case 
detection, while the moderate specificities may lead to a number 
of false-positive cases. These should be reviewed at a second tier 
of screening by staff with a higher level of skills. 
In order to implement these interventions as widely as possible, 
data on suitability and feasibility are needed. Such a pilot 
programme is underway in the HIV/neuropsychiatry programme 
in the Western Cape. We suggest that existing lay counsellors or 
nurses be trained to administer these tools. A study comparing the 
results obtained by trained mental health professionals and lay 
interviewers needs to be done to establish levels of agreement. 
Following this, additional measures, together with an assessment 
of true case-ness using a semi-structured diagnostic interview 
(such as the MINI neuropsychiatric interview), should be done to 
establish the local diagnostic validity and utility of the SAMISS and 
IHDS. The impact of these tools on clinic function, acceptability to 
personnel and ease of use should be measured. Cases detected 
by lay counsellors or nurses should then be referred to a mental 
health nurse for more detailed assessment. True cases may be 
managed on site by community mental health services, or referred 
to secondary support clinics if needed. Information regarding the 
reasons for referral out should be captured, so as to plan future 
services and needs. 
Resources for HIV and mental health are scarce. To our 
knowledge, there are very few dedicated HIV psychiatry services 
in South Africa. The role of HIV psychiatrists should be to develop 
and co-ordinate services to PLWHA using existing frameworks. 
Additional support and development should be added. This may 
take the form of medical officers to manage referred patients, and 
lay counsellors and nurses to provide primary care screening and 
treatment. Once feasibility and effectiveness have been shown, 
the programme could be expanded to reach all PLWHA. These 
tasks need to shift to the non-psychiatrist. With suitable training 
and support, it is possible that mental health services can be 
integrated into routine ARV care. Lessons from this disease may 
then be transferred into general primary care settings. 
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